Physician profile
Daniel S Weikert
NPI 1902838550
$2,707.44
in general payments reported to CMS, 2019-2025
9 companies · $473 in 2025
The $473 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $420 · 2020: $89.70 · 2021: $127 · 2022: $240 · 2023: $598 · 2024: $759 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,830.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,944.35 | 2019-2025 | Clareon, Clareon Panoptix Pro, Hydrus Microstent |
| Abbvie INC. | $393.12 | 2022-2024 | Durysta, Vuity, Alphagan P |
| Allergan, INC. | $197.40 | 2021-2022 | |
| Mindray Ds USA, INC. | $47.38 | 2025 | A7 Anesthesia System |
| Alcon Research LLC | $36.61 | 2019 | |
| Mallinckrodt Hospital Products INC. | $28.92 | 2021 | |
| Mallinckrodt Enterprises LLC | $22.96 | 2019 | |
| Laborie Medical Technologies Corp. | $21.25 | 2024 | Endosheath Technology |
| Carl Zeiss Meditec, INC. | $15.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Weikert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.